Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention
Chinedu Udeh‐Momoh, Bang Zheng, Anna Matton, et al.
The Journal of Prevention of Alzheimer s Disease (2021), pp. 1-10
Open Access | Times Cited: 25

Showing 25 citing articles:

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
Dallas P. Veitch, Michael W. Weiner, Melanie J. Miller, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 1, pp. 652-694
Open Access | Times Cited: 35
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
María Pascual‐Lucas, José Antonio Allué, Leticia Sarasa, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 29
Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia
Lise Colmant, Emilien Boyer, Thomas Gérard, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1173-1173
Open Access | Times Cited: 6
Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis
Kenta Noda, Yeongjoo Lim, Rei Goto, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103911-103911
Closed Access | Times Cited: 6
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
Doris P. Molina‐Henry, Rema Raman, Andy Liu, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 3827-3838
Open Access | Times Cited: 6
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Roxanna Korologou‐Linden, J. Kalsi, Dimitra Kafetsouli, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 6
Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study
Noriyuki Kimura, Kotaro Sasaki, Teruaki Masuda, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access
Is blood pTau a reliable indicator of the CSF status? A narrative review
Annibale Antonioni, Emanuela Maria Raho, Francesco Di Lorenzo
Neurological Sciences (2023) Vol. 45, Iss. 6, pp. 2471-2487
Closed Access | Times Cited: 11
Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology
Fengfeng Pan, Yanlu Huang, Xiao Cai, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 9
Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients
Yanlu Huang, Yuehua Li, Fang Xie, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 28, Iss. 12, pp. 2195-2205
Open Access | Times Cited: 15
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
Julien Delrieu, Randall J. Bateman, J. Touchon, et al.
The Journal of Prevention of Alzheimer s Disease (2022)
Open Access | Times Cited: 14
Effect of β-amyloid on blood-brain barrier properties and function
Irina Yu. Petrushanko, Vladimir A. Mitkevich, Alexander А. Makarov
Biophysical Reviews (2023) Vol. 15, Iss. 2, pp. 183-197
Open Access | Times Cited: 8
Comparing the effects of olfactory-based sensory stimulation and board game training on cognition, emotion, and blood biomarkers among individuals with dementia: A pilot randomized controlled trial
Li-Jung Lin, Kuan‐yi Li
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 10
Clinical utility of an antibody‐free LC‐MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study
José Antonio Allué, María Pascual‐Lucas, Leticia Sarasa, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2023) Vol. 15, Iss. 2
Open Access | Times Cited: 4
Advances and Future Trends in the Detection of Beta-Amyloid: A Comprehensive Review
Auroop R. Ganguly, Srivalliputtur Sarath Babu, Sumanta Ghosh, et al.
Medical Engineering & Physics (2024) Vol. 135, pp. 104269-104269
Closed Access | Times Cited: 1
Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors
Noriyuki Kimura, Tomoki Aota, Yasuhiro Aso, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 2
A Multichannel Fluorescent Tongue for Amyloid-β Aggregates Detection
Fei Li, Lingjia Zhou, Xu Gao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14562-14562
Open Access | Times Cited: 4
Amyloid fil rouge from invertebrate up to human ageing: A focus on Alzheimer disease
Magda de Eguileor, Annalisa Grimaldi, Laura Pulze, et al.
Mechanisms of Ageing and Development (2022) Vol. 206, pp. 111705-111705
Closed Access | Times Cited: 3
O Potencial dos Biomarcadores Sanguíneos na Identificação Precoce da Doença de Alzheimer
Francisco Samuel Estrela Dantas, Maria Clara Maniçoba Ferreira de Lima, Paulo André Oliveira de Sá, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 4, pp. 1459-1471
Open Access
What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation
Zhitao Hou, Ailin Sun, Yan Li, et al.
Mediators of Inflammation (2024) Vol. 2024, pp. 1-23
Open Access
Considering Biomarkers of Neurodegeneration in Alzheimer’s Disease: The Potential of Circulating Cell-Free DNA in Precision Neurology
Chad Pollard, Erin R. Saito, Jeffrey M. Burns, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 11, pp. 1104-1104
Open Access
Plasma levels of soluble RAGE, AGEs and AOPPs at the early stage of amyotrophic lateral sclerosis: A preliminary study
Judyta K. Juranek, Adam Osowski, Joanna Wojtkiewicz, et al.
Polymers in Medicine (2023) Vol. 53, Iss. 2, pp. 105-110
Open Access | Times Cited: 1
Dementia Prevention: A Global Challenge in Urgent Need of Solutions
Geraint Price, Chinedu Udeh‐Momoh, Miia Kivipelto, et al.
The Journal of Prevention of Alzheimer s Disease (2022)
Open Access | Times Cited: 2
BIOMARCADORES SANGUÍNEOS APLICADOS AO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER
Eduarda Mirelle de Morais Gomes, Adrielle Antonia da Silva, Beatriz Santiago Guerra
Editora e-Publicar eBooks (2023), pp. 205-218
Open Access
Plasma Proteomics To Identify the Biomarkers and Pathogenesis of Mild Cognitive Impairment
Zhitao Hou, Ailin Sun, Xiaochen Song, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top